Grifols S.A (G0FB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Grifols S.A (G0FB) has a cash flow conversion efficiency ratio of 0.057x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€430.86 Million ≈ $503.73 Million USD) by net assets (€7.60 Billion ≈ $8.89 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Grifols S.A market cap and net worth for the company's overall valuation and market capitalisation.
Grifols S.A - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Grifols S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Grifols S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Grifols S.A ranked by their cash flow conversion efficiency. Explore Grifols S.A cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Moelis & Co
NYSE:MC
|
0.361x |
|
Hanjaya Mandala Sampoerna Tbk PT
JK:HMSP
|
0.096x |
|
Ningxia Orient Tantalum Industry Co Ltd
SHE:000962
|
-0.065x |
|
Beijing Yanjing Brewery Co Ltd
SHE:000729
|
0.073x |
|
Anhui Yingjia Distillery Co Ltd
SHG:603198
|
0.047x |
|
ENTAIN PLC UNSP.ADR/1
F:6GI0
|
N/A |
|
Marathon Digital Holdings Inc
NASDAQ:MARA
|
-0.268x |
|
Inficon Holding
SW:IFCN
|
0.165x |
Annual Cash Flow Conversion Efficiency for Grifols S.A (2016–2025)
The table below shows the annual cash flow conversion efficiency of Grifols S.A from 2016 to 2025. View Grifols S.A stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €7.60 Billion ≈ $8.89 Billion |
€1.05 Billion ≈ $1.22 Billion |
0.138x | +31.40% |
| 2024-12-31 | €8.61 Billion ≈ $10.06 Billion |
€902.00 Million ≈ $1.05 Billion |
0.105x | +260.06% |
| 2023-12-31 | €7.51 Billion ≈ $8.78 Billion |
€218.69 Million ≈ $255.67 Million |
0.029x | +2365.22% |
| 2022-12-31 | €8.46 Billion ≈ $9.89 Billion |
€-10.87 Million ≈ $-12.70 Million |
-0.001x | -101.75% |
| 2021-12-31 | €8.15 Billion ≈ $9.52 Billion |
€596.98 Million ≈ $697.93 Million |
0.073x | -55.65% |
| 2020-12-31 | €6.72 Billion ≈ $7.86 Billion |
€1.11 Billion ≈ $1.30 Billion |
0.165x | +98.81% |
| 2019-12-31 | €6.85 Billion ≈ $8.00 Billion |
€568.93 Million ≈ $665.14 Million |
0.083x | -47.07% |
| 2018-12-31 | €4.70 Billion ≈ $5.49 Billion |
€737.43 Million ≈ $862.13 Million |
0.157x | -32.21% |
| 2017-12-31 | €3.63 Billion ≈ $4.25 Billion |
€841.75 Million ≈ $984.09 Million |
0.232x | +56.07% |
| 2016-12-31 | €3.73 Billion ≈ $4.36 Billion |
€553.28 Million ≈ $646.84 Million |
0.148x | -- |
About Grifols S.A
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, … Read more